SCHEMBL23037435

SCHEMBL23037435

CC(OC(N)=O)c1cc(F)ccc1OC(F)(F)CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.30
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
KMT2A Q03164 1/20 0.30
SCN9A Q15858 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2C19 P33261 1/20 0.30
PKM P14618 1/20 0.30
KDM4E B2RXH2 1/20 0.30
TSHR P16473 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
FFAR1 O14842 1/20 0.30
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23037433 1.00 TACR1 (0.31) TACR1L3MBTL1MEN1MAPTHPGD
SCHEMBL23037399 0.81 PDE2A (0.34) MEN1KMT2ASCN9APSEN1PSEN2
SCHEMBL23037395 0.81 PDE2A (0.34) MEN1KMT2ASCN9APSEN1PSEN2
SCHEMBL28657163 0.76 CARM1 (0.36) L3MBTL1MEN1MAPTHPGDKMT2A
SCHEMBL28657164 0.76 CARM1 (0.36) L3MBTL1MEN1MAPTHPGDKMT2A
SCHEMBL9175291 0.75 CES2 (0.45) L3MBTL1MEN1MAPTHPGDKMT2A
SCHEMBL28661518 0.75 HTT (0.39) MEN1KMT2APKMKDM4EFFAR1
SCHEMBL28661520 0.75 HTT (0.39) MEN1KMT2APKMKDM4EFFAR1
SCHEMBL28661522 0.75 HTT (0.39) MEN1KMT2APKMKDM4EFFAR1
SCHEMBL23047241 0.74 AAK1 (0.41) SCN9ATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220162218-A1 DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF PRIMEGENE (BEIJING) CO., LTD. (CN) 2022-05-26 US disclosed
EP-3786167-A1 DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF Primegene (Beijing) Co., Ltd. (CN) 2021-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162218-A1 DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF SRC, CYP11B1, LCK TACR1 1598/4885L3MBTL1 2809/4885MEN1 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.